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SUMMARY 
Idiopathic pulmonary fibrosis (IPF) is characterized by distorted lung architecture 
and loss of respiratory function. Enhanced (myo)-fibroblast activation, ECM 
deposition, and alveolar epithelial type II (ATII) cell dysfunction contribute to IPF 
pathogenesis. However, the molecular pathways linking ATII cell dysfunction with 
the development of fibrosis are poorly understood. Here, we demonstrate, in a 
mouse model of pulmonary fibrosis, increased proliferation and altered 
expression of components of the WNT/β-catenin signalling pathway in ATII cells. 
Further analysis revealed that expression of WNT1-inducible signalling protein–1 
(WISP1), which is encoded by a WNT target gene, was increased in ATII cells in 
both a mouse model of pulmonary fibrosis and patients with IPF. Treatment of 
mouse primary ATII cells with recombinant WISP1 led to increased proliferation 
and epithelial-mesenchymal transition (EMT), while treatment of human lung 
fibroblasts with recombinant WISP1 enhanced deposition of ECM components. In 
the mouse model of pulmonary fibrosis, neutralizing mAbs specific for WISP1 
reduced the expression of genes characteristic of fibrosis and reversed the 
expression of genes associated with EMT. More importantly, these changes in 
gene expression were associated with marked attenuation of lung fibrosis, 
including decreased collagen deposition and improved lung function and survival. 
Our study thus identifies WISP1 as a key regulator of ATII cell hyperplasia and 
impaired epithelial-mesenchymal interaction as well as a potential therapeutic 
target for attenuation of pulmonary fibrosis. 
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ZUSAMMENFASSUNG 
Fibrosierende Lungenerkrankungen sind durch eine vermehrte Ansammlung 
extrazellulärer Matrix und Proliferation der interstiziellen Fibroblasten  
charakterisiert. Dies führt zu einem kompletten Gewebsumbau der Lunge und 
einem funktionellem Verlust an Alveolarraum. Im Verlauf der Erkrankung führen 
wiederholte epitheliale Schädigungen mit versuchten Reparaturvorgängen zu 
einer Veränderung des Genexpressionsprofils der alveolären Epithelzellen  Typ II 
(ATII-Zellen), was zu einer weiteren Aktivierung der Fibroblasten zu 
Myofibroblasten führt. In dieser Studie wurden ATII Zellen aus gesunden bzw. 
fibrotischen murinen Lungen  isoliert und untersucht. Mittels Proliferations-
analysen, Immunfluoreszenz, quantitativer RT-PCR sowie Microarrayanalysen, 
konnten wir eine gesteigerte Proliferation und veränderte Genexpression der 
fibrotischen ATII Zellen nachweisen. Insbesondere der WNT/β-catenin Signalweg 
war differenziell reguliert und aktiviert. Weitere Analysen zeigten, dass das 
WNT1 inducible signalling protein (WISP) 1 in den ATII Zellen in der 
experimentellen als auch humanen idiopathischen pulmonalen Fibrose vermehrt 
exprimiert wird.  Die Stimulation von primären ATII Zellen mit rekombinanten 
WISP1 führte zu einer gesteigerten Proliferation und epihtelialen-
mesenchymalen Transition (EMT), während eine Stimulation von humanen 
Fibroblasten zu einer gesteigerten Produktion und Deposition von extrazellulärer 
Matrix führte. In der Bleomycin-induzierten Lungenfibrose führte die Gabe von 
neutralisierenden Antikörpern gegen WISP1 zu einer Reduktion von 
profibrotischen Genen sowie EMT-Markern. Eine deutliche Abschwächung der 
Lungenfibrose mit verbesserter Lungenarchitektur konnte weiterhin durch 
immunhistochemische Analysen und Quantifizierung von Bestandteilen der 
extrazellulären Matrix, sowie einer Verbesserung der Lungenfunktion und des 
Überlebens, bestätigt werden. Unsere Studie identifiziert WISP1 als 
profibrotischen Mediator, der an der gestörten epithelialen-mesenchymalen 
Interaktion beteilgt ist. Eine Hemmung von WISP1 könnte eine mögliche neue 
Therapieform für Patienten mit IPF darstellen.  
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INTRODUCTION 
Diffuse parenchymal lung diseases 
Diffuse parenchymal lung diseases (DPLDs) are characterized by progressive 
fibrosis of the pulmonary interstitium, which subsequently leads to distortion of 
the normal lung architecture and respiratory failure (1). Fibrotic alterations can 
occur secondary to lung injury, provoked e.g. by chemotherapy, toxin inhalation, 
collagen vascular disease, or as an idiopathic entity in the form of idiopathic 
interstitial pneumonias (IIP) (1-3)}. IIPs are a heterogeneous group of rare 
DPLDs of unknown etiology. IIPs are divided into idiopathic pulmonary fibrosis 
(IPF), which is the most common form of IIP, and non-IPF. The different forms 
are mainly differentiated by histological, radiological and clinical features. Non-
IPFs comprises of nonspecific interstitial pneumonia (NSIP), cryptogenic 
organizing pneumonia (COP), acute interstitial pneumonia (AIP), respiratory 
bronchiolitis-associated interstitial lung disease (RB-ILD), desquamantative 
interstitial pneumonia (DIP) and lymphocytic interstitial pneumonia (LIP). IPF 
differs prognostically and therapeutically from non-IPFs IIPs, which underlines 
the importance of a stringent diagnostic process, which includes close 
communication between clinician, radiologist, and pathologist (1, 2). 
 
IPF - Clinical features 
IPF exhibits a progressive course with a poor prognosis. IPF occurs mainly in 
people aged 50 yrs and is more common in men. The prevalence of IPF is 
estimated at 15-40 cases per 100000 per year, incidence 7 cases per 100000 per 
year. Smoking has been identified as potential risk factor. IPF has an insidious 
onset characterized by unexplained dyspnoea, especially on exertion, and 
nonproductive cough for a minimum period of 3 months (2, 4-6). Recurrent 
respiratory infections and an acute exacerbation are frequent and often 
responsible for acute deterioration (4, 7, 8). Ultimately, IPF leads to peripheral 
edema and right heart failure. The mean survival from the time of diagnosis is 3-5 
years regardless of treatment, as IPF exhibit very limited responsiveness to 
currently available therapies (2, 9-11). Historically, oral corticosteroids, either 
7 
 
alone or in combination with immunsuppressiva have been used. Evidence for 
the effectiveness of these drugs from controlled studies, however, is missing (6, 
12). A number of other treatments such as interferon-γ or pirfenidone have not 
proved effective (6, 13, 14). The antioxidant N-acetylcysteine has been shown to 
slow the rate of decline in lung function but does not significantly alter mortality 
(15). Information from these studies and consensus statements suggests that a 
combination of low-dose prednisolone in combination with azathioprine and 
antioxidant treatment is the preferred choice up to now (16). It has to be pointed 
out; however, that lung transplantation remains the only therapeutic intervention 
with a known survival benefit for IPF patients (17, 18).  
 
 
Figure I1. Kaplan-Meier survival curves for patients grouped by combining HRCT and 
histopathological features as follows: histopathologic pattern showing NSIP and HRCT 
interpreted as indeterminate or NSIP (n=23, dotted line); histopathologic pattern showing 
UIP and HRCT interpreted as indeterminate or NSIP (n=46, dashed line); and 
histopathologic pattern showing UIP and HRCT interpreted as UIP (n=27, solid line), 
p=0.001. + = last follow-up visit; circle = death. (19) 
 
IPF –Pathological and histopathological features 
Next to clinical features, such as age >50 yrs, dyspnoea and nonproductive 
cough >3 months, several major criteria are essential for the diagnosis of IPF. 
These include 1) the exclusion of other known causes of DPLD; 2) abnormal 
pulmonary function tests exhibiting restriction and impaired gas exchange; 3) 
bibasilar reticular abnormalities with ground-glass opacities on high resolution 
computer tomography, in particular lower-lobe honeycombing; and 4) 
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transbronchial lung biopsy or bronchoalveolar lavage, excluding other causes (1, 
20-23). 
 
Figure I2. High-resolution computed tomography (HRCT) from an IPF patient. Peripheral reticular 
abnormalities with minimal ground-glass opacities and cystic structures surrounded by thickened 
white lines (honey combing). 
 
A definitive diagnosis of IPF, however, requires a surgical lung biopsy and 
detailed histopathological analysis. The typical pathological pattern defining IPF 
is the usual interstitial pneumonia (UIP) pattern, which is characterized by the 
following observations: 1) fibrotic zones with dense collagen and scattered 
fibroblast foci in particular in subpleural and paraseptal areas, 2) a 
heterogeneous pattern with normal and abnormal lung, and 3) comparatively little 
nonspecific chronic inflammation compared with other IIPs (24-27). The 
fibroblastic foci consist of activated (myo)-fibroblasts and are a cardinal feature of 
UIP (26, 27). Fibroblast foci are mainly in close proximity with injured hyperplastic 
alveolar epithelium, largely composed of alveolar epithelial type II (ATII) cells. 
Interestingly, only mild inflammation is present in these areas. While historically, 
inflammatory processes were thought to trigger and facilitate the progression of 
IPF, this view has been questioned, due to the above mentioned 
histopathological observations and ineffectiveness of anti-inflammatory therapy in 
IPF (28-30). In addition, mortality of IPF patients has been correlated with the 
presence of fibrotic foci and adjacent failure of reepithelization, but not with 
inflammation (25, 31). 
 
9 
 
 
Figure I3. Histopathological pictures of IPF. Tissue sections were stained for smooth muscle actin 
(brown), to visualize the activated fibroblasts in fibroblast foci (magnification 10x (left) and 40x 
(right)). 
 
Idiopathic pulmonary fibrosis (IPF) - Pathomechanism 
Altogether, the above described observations led to the concept that repetitive 
alveolar epithelial injury and impaired repair mechanisms, in the presence or 
absence of local inflammation, play a central role in IPF/UIP pathogenesis, 
leading to impaired epithelial-mesenchymal interaction and fibroblast activation 
(28-30). 
While the initial injury in IPF is affecting the alveolar epithelium, the interstitial 
fibroblast / activated (myo)-fibroblast represents the key effector cell responsible 
for the increased ECM deposition that is characteristic for IPF (32-34). Thus, a 
key question in IPF that needs to be elucidated is: What is the origin of the 
activated (myo)-fibroblast? Three major approaches exist to answer this 
question: First, resident pulmonary fibroblasts proliferate in response to 
fibrogenic cytokines and growth factors, such as transforming growth factor 
(TGF)-β, thereby increasing the fibroblast pool by local fibroproliferation (33, 34). 
Second, bone marrow-derived circulating fibrocytes cells traffic to the lung during 
experimental lung fibrosis, and may serve as progenitors for interstitial fibroblasts 
(35-37). Third, alveolar epithelial cells may turn into fibroblast-like cells, a process 
called epithelial-to-mesenchymal transition (EMT) (38, 39). EMT is well described 
in the process of embryonic development, as well as in oncogenic progression 
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and metastasis (40, 41). Importantly, it was recently demonstrated that TGF-β 
induces EMT in alveolar epithelial cells in vitro and in vivo (38, 39, 42).  
The current “alveolar epithelial injury” concept of IPF/UIP further demand the 
following question: What are the mediators of alveolar epithelial cell injury and 
impaired epithelial-mesenchymal interaction in IPF? Epithelial-mesenchymal 
interactions are a prerequisite for proper lung development and homeostasis. In 
the adult lung, epithelial-mesenchymal interactions are responsible for the 
maintenance of the trophic alveolar unit, and are essential for normal lung 
function and gas exchange. Impaired epithelial-mesenchymal crosstalk between 
ATII cells and subepithelial fibroblasts, however, has recently been shown to 
contribute to the pathobiology of IPF (30, 43). Although several soluble mediators 
released by ATII cells, such as TGF-β1 (44), angiotensin II (45, 46), or interleukin 
(IL)-1β (47), have been assigned a clear pathogenic role in IPF and experimental 
models thereof, therapeutic options neutralizing their activity have not been 
successful in the clinical use as of yet (6, 48, 49). In addition, only limited 
information is available about the phenotype and gene regulatory networks of 
ATII cells in lung fibrosis. 
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AIM OF THE STUDY 
It is well-accepted that repetitive alveolar epithelial injury and impaired repair 
mechanisms represents a trigger event in the development of IPF, causing 
impaired epithelial-mesenchymal interaction and fibroblast activation in IPF. In 
this study we sought to address the following key question: 
 
“What are the mediators of alveolar epithelial cell injury and impaired epithelial-
mesenchymal interaction in IPF?” 
 
We aimed to 
1)  characterize the ATII cell phenotype in experimental and human idiopathic 
pulmonary fibrosis; 
2)  determine alterations in the gene and protein expression of ATII cells in 
experimental and human idiopathic pulmonary fibrosis; 
3) identify new (secreted) proteins involved in epithelial-mesenchymal 
interactions; 
4)  evaluate the therapeutic suitability of identified proteins 
 
In detail, we initially performed an unbiased whole genome microarray analysis of 
primary mouse ATII cells isolated from fibrotic lungs. We present a 
comprehensive analysis of the ATII cell phenotype in experimental and human 
idiopathic pulmonary fibrosis, and report altered expression of cell- and disease 
specific proteins in lung fibrosis in vivo and in vitro. In addition, we analyzed the 
effects of proteins of interest on ATII cell and fibroblast function. Moreover, we 
depleted the protein of interest using neutralizing antibodies in an experimental 
lung fibrosis model to evaluate its therapeutic potential in vivo. 
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Equipment 
ABI PRISM 7500 Detection System  Applied Biosystems, USA 
Bioanalyzer 2100      Agilent Technologies, USA 
Developing machine X Omat 2000   Kodak, USA 
Electrophoresis chambers     Bio-Rad, USA 
Microscope LEICA AS MDW    Leica, Germany 
Fusion A153601 Reader Packard   Bioscience, Germany 
Gel blotting paper 70 × 100 mm    Bioscience, Germany 
GS-800TM Calibrated Densitometer   Bio-Rad, USA 
Light microscope Olympus BX51    Olympus, Germany 
Microsprayer IA-1C     Penn-Century, USA 
PCR-thermocycler      MJ Research, USA 
Quantity One software     Bio-Rad, USA 
Radiographic film X-Omat LS    Sigma-Aldrich, Germany 
Reagents 
Acetonitrile       Roth, Germany 
Agarose       Invitrogen, UK 
Albumine, bovine serum     Sigma-Aldrich, Germany 
Bleomycin sulphate     Almirall Prodesfarme, Spain 
CompleteTM Protease inhibitor    Roche, Germany 
DAPI       Roche Diagnostics, Germany 
D-(+)-Glucose      Sigma-Aldrich, Germany 
D-MEM medium      Gibco BRL, Germany 
D-MEM medium      Sigma-Aldrich, Germany 
DNA Ladder (100 bp, 1kb)    Promega, USA 
EDTA / EGTA     Promega, USA 
Dulbecco’s phosphate buffered saline  PAA Laboratories, Austria 
ECL Plus Western Blotting Detection System  Amersham Biosciences, UK 
Fetal calf serum (FCS)     Gibco BRL, Germany 
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Antibodies 
α-smooth muscle actin (αSMA)   Chemicon International, USA 
β-actin       Sigma-Aldrich, Germany 
Ki67       Molecular Probes, USA  
phospho-p38 MAPK (Thr180/Tyr182)  CellSignalling Technology, USA 
total p38 MAPK     CellSignalling Technology, USA 
phospho-p42/44 MAPK (Thr202/Tyr204) CellSignalling Technology, USA 
total p42/44 MAPK     CellSignalling Technology, USA  
pro-surfactant protein C (SPC)    Chemicon International, USA 
pan-cytokeratin (panCK)    Dako 
tight junction protein (TJP) 1    Zymed Laboratories 
α-tubulin      Santa Cruz, USA 
lamin A/C       Santa Cruz, USA 
CD45       BD Biosciences 
CD16/32      BD Biosciences 
e-cadherin (ECAD)      BD Biosciences 
occludin (OCCL)      BD Biosciences 
total β-catenin     CellSignalling Technology, USA 
total GSK-3β      CellSignalling Technology, USA 
phospho-Histone 3     CellSignalling Technology, USA 
WNT1       Abcam 
β-galactosidase (β-GAL)    Abcam  
type 1 collagen 1 (COL1A1)   Biodesign 
clara cell specific protein (CCSP)   Millipore/Upstate.  
WISP1 (AF 1680, MAB 1680, MAB 1627)  R&D Systems, USA 
WISP1 (ab10737)     Abcam 
Recombinant  proteins  
WISP1, TGF-β1, WNT3A, CTGF   R&D Systems, USA 
KGF was a kind gift from Veronica Grau (University of Giessen). 
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Mouse model of Bleomycin-induced lung fibrosis 
Six to eight week-old pathogen-free female C57BL/6N mice were used 
throughout this study. All experiments were performed in accordance with the 
guidelines of the Ethic’s Committee of University of Giessen School of Medicine 
and approved by the local authorities. Mice had free access to water and rodent 
laboratory chow. Bleomycin sulphate was dissolved in sterile saline solution and 
applied by microsprayer administered as a single dose of 0.08 mg in 200 µl 
saline solution per animal (≈ 5U/kg body weight). Control mice received 200 µl 
saline. Lung tissues were excised and snap frozen, or inflated with 4 % (m/v) 
paraformaldehyde in phosphate-buffered saline (PBS, PAA Laboratories) at 21 
cm H2O pressure for histological analyses. 
Mouse model of WNT activation 
The TOPGAL mice were purchased from Jackson Laboratories. The derivation of 
TOPGAL mice has been described in detail previously (50). Mice were bred 
under specific pathogen-free (SPF) conditions. The following primer were used 
for identification of transgenic animals: Lac(Z)-F 5-
gttgcagtgcacggcagatacacttgctga-3´;Lac(Z)-R5´-gccactggtgtgggccataattcattcgc 
-3´. Four to eight week old mice were used for all experiments. 
Alveolar epithelial cells isolation and culture 
Primary mouse alveolar epithelial type II (ATII) cells were isolated from saline- 
and bleomycin-treated mice. Isolation of primary alveolar epithelial cells was 
performed as described by Corti et al. (51). Mice were killed by an overdose of 
isoflurane and exsanguinated by cutting the inferior vena cava. Lungs were 
lavaged 2× with 300 µl sterile PBS. After opening the thorax, a small incision was 
made in the left ventricle, a 26-gauge cannula was placed into the right ventricle 
and lungs were perfused with PBS until they were visually free of blood. A small 
cut was made into the exposed trachea to insert a shortened 21-gauge cannula 
that was firmly fixed and a total volume of 1.5 ml of sterile Dispase followed by 
500 μl of sterile 1% low-melting agarose in PBS-/- was administered into the 
lungs. After 2 min of incubation, the lungs were removed and placed into a 
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Falcon tube containing 2ml of Dispase for 40 min. Lungs were then transferred 
into a culture dish containing isolation media and DNase, and the tissue was 
carefully dissected from the airways and large vessels. The cell suspension was 
sequentially filtered through 100-, 20-, and 10-μm nylon meshes and centrifuged 
at 200 × g for 10 min. The pellet was resuspended in isolation media and a 
negative selection for lymphocytes/macrophages was performed by incubation 
on CD16/32- and CD45-coated Petri dishes for 30 min at 37 °C. Negative 
selection for fibroblasts was performed by adherence for 45 min on cell culture 
dishes. Cell purity and viability was analyzed in freshly isolated ATII cells directly 
after isolation. Cell purity was routinely assessed by epithelial cell morphology 
and immunofluorescence analysis of panCK, pro-SPC (both positive), αSMA, and 
CD45 (both negative) of cytocentrifuge preparations of ATII cells. Cell viability 
was checked by Trypan Blue exclusion. ATII cells used throughout this study 
demonstrated a 95 ± 3% purity and > 97% viability. Finally, ATII cells were 
suspended in DMEM + 10% FCS, 2 mM L-glutamine, 100 units/ml penicillin, and 
100 g/ml streptomycin, and cultured for 24h to allow attachment. Phenotypic 
characterisation was done after this time period. After media change cells were 
cultured for a maximum of 2 days in a humidified atmosphere of 5% CO2 at 37 
°C. 
Primary human alveolar epithelial type II (ATII) cells were isolated as previously 
described (52). We isolated human ATII cells from explants after transplantation. 
The tissue was carefully dissected from the airways and large vessels and 
subsequently washed 3x in PBS -/- at 4°C. The tissue was minced manually and 
pipett thoroughly during enzymatic digestion with Dispase for 90min at RT. The 
suspension was sequentially vacuum-filtered through 100-, 50-, and 20-μm nylon 
meshes and centrifuged at 200 × g for 10 min. The pellet was resuspended in 
isolation media and a Ficoll gradient was performed. The ATII cell enriched 
interphase  was incubated with anti- CD3 / CD14 antibodies for 30 min at 37°C 
followed by magnetic separation of contaminating leukocytes using the Magnetic 
Activated Cell Sorting (MACS) system (Miltenyi Biotec). Negative selection for 
fibroblasts was performed by adherence for 45 min on cell culture dishes for up 
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to three times. The purity and viability of ATII cell preparations was assessed as 
described for mouse ATII cells and was consistently >90% and >95%, 
respectively. Freshly isolated human ATII cells were used for gene expression 
analysis. The study protocol was approved by the Ethics Committee of the 
Justus-Liebig-University School of Medicine (AZ 31/93). Informed consent was 
obtained from each subject for the study protocol.   
Conditioned media 
Primary ATII cells were isolated and cultured in DMEM supplemented with 10% 
FCS. Twenty-four hours after plating, culture media and nonadherent cells were 
removed, attached cells washed × 2 with PBS, and cells replenished with DMEM. 
The cells were then cultured for another 24 h, after which conditioned medium 
(CM) was collected. CM was centrifuged at 2.000 g (10 min, 4°C) to remove 
cellular debris, and transferred to a sterile container.  
Human tissues 
Lung tissue biopsies were obtained from 15 IPF patients with histological usual 
interstitial pneumonia (UIP) pattern (4 females, 11 males; mean age = 58 ± 8 
years; mean VC= 48% ± 7%; mean TLC = 50% ± 5%; mean DLCO/VA = 23% ± 
3%; O2 =2–4 l/min; PaO2 = 49–71 mmHg, PaCO2= 33–65 mmHg) and 9 control 
subjects (organ donors; 4 females, 5 males; mean age 42 ± 10 years). Individual 
patient characteristics are shown in Table S1. Furthermore, lung tissue biopsies 
were obtained from four patients with NSIP pattern (mean age 55 ± 5 years; 2 
females, 2 males) and six patients with chronic obstructive pulmonary disease 
(COPD; mean age 54 ± 4 years; 4 females, 2 males). Samples were immediately 
snap frozen or placed in 4% (w/v) paraformaldehyde after explantation. The 
study protocol was approved by the Ethics Committee of the Justus-Liebig-
University School of Medicine (AZ 31/93). Informed consent was obtained in 
written form from each subject for the study protocol.  
Laser-assisted microdissection 
Laser-assisted microdissection was performed as previously described (53). In 
brief, 10 μm cryosections were mounted on glass slides, stained with hemalaun 
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for 45 s, immersed in 70% and 96% ethanol, and stored in 100% ethanol until 
use. Alveolar septae were selected and microdissected with a sterile 30 G needle 
under optical control using the Laser Microbeam System (P.A.L.M.). 
Microdissected tissues were then transferred into reaction tubes containing 200 
μl RNA lysis buffer and samples processed for RNA analysis. 
Gene expression profiling 
Primary ATII cells were isolated from normal and fibrotic mouse lungs 14 days 
after saline or bleomycin instillation, respectively, and directly used for whole 
genome microarray analysis. Freshly isolated ATII cells were pooled from 6 
different saline- or bleomycin-treated mice. Three independent groups of healthy 
and fibrotic samples were used for RNA extraction. Total RNA was extracted as 
described and RNA quality assessed by capillary electrophoresis using the 
Bioanalyzer 2100 (Agilent Technologies). All samples contained 0.3 - 1.0 µg 
RNA, which was preamplified and labelled using the Low Input RNA T7 kit 
(Agilent Technologies) according to the manufacturer’s instructions. Three 
samples each (saline- and bleomycin-treated mice) were labelled with Cy3 and 
Cy5. The labelled RNA was hybridized overnight to 44K 60mer oligonucleotide 
spotted microarray slides (Human Whole Genome 44K; Agilent Technologies). 
Slides were washed with different stringencies, dried by gentle centrifugation, 
and scanned using the GenePix 4100A scanner (Axon Instruments). Data 
analysis was performed with GenePix Pro 5.0 software, and calculated fore- and 
background intensities for all spots were saved as GenePix results files. Stored 
data were evaluated using the "R" software (http://www.cran.r-project.org/) and 
the "limma" package from BioConductor (http://www.bioconductor.org). 
Experimental conditions and results from all microarray experiments are outlined 
in detail in the Supplement, according to the MIAME guidelines. 
Reverse transcriptase (RT)-PCR and quantitative (q) RT-PCR 
Total RNA was extracted using Qiagen extraction kits according to the 
manufacturer´s protocol, and cDNAs were generated by reverse transcription 
using SuperScript™ II (Invitrogen). Quantitative PCR was performed using 
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fluorogenic SYBR Green and the Sequence Detection System 7500 (Applied 
Biosystems). Hydroxymethylbilane synthase (HMBS) and hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) for mouse and human, respectively and 
both ubiquitously and equally expressed genes that are free of pseudogenes, 
were used as reference genes in all qRT-PCR reactions. PCR was performed 
using the primers listed in Table S2 and 3, used at a final concentration of 200 
nM. Relative transcript abundance of a gene is expressed in ΔCt values (ΔCt = 
Ctreference – Cttarget). Relative changes in transcript levels compared to controls are 
expressed as ΔΔCt values (ΔΔCt = ΔCttreated – ΔCtcontrol). All ΔΔCt values 
correspond approximately to the binary logarithm of the fold change.  
Immunofluorescence/-histochemistry 
For immunofluorescence analysis, cells were plated on chamber slides, fixed with 
acetone/methanol (1:1), and blocked for non-specific binding sites with 3% 
(m/vol) BSA. Fixed cells were incubated with the indicated primary antibodies for 
60 min in PBS containing 0.1% (m/vol) BSA. Indirect immunofluorescence was 
performed by incubation with FITC-/ or Alexa 555-conjugated secondary 
antibodies (Zymed and Molecular Probes, respectively) for 45 min. Nuclei were 
visualized by 4,6-diamidino-2-phenylindole (DAPI) staining  for 10 min. For 
immunohistochemical analysis, lungs were processed using standard 
procedures, embedded in paraffin, and mounted on poly-L-lysine coated slides. 
Antigen retrieval was performed in 6.5 mM sodium citrate, pH 6.0, in a pressure 
cooker, after which endogenous peroxidase activity was quenched with 3% (v/v) 
H2O2 for 20 min. Proteins of interest were visualized using the Histostain Plus Kit 
(Zymed). 
Detection of β-galactosidase in TOPGAL mice 
The β-galactosidase was detected using the X-GAL (5-bromo-4-chloro-3-indolyl 
β-D-galactosidase) reporter gene staining kit from Sigma-Aldrich. Lung tissues 
were excised and immediately transferred to fixative containing 0.2% 
glutaraldehyde, 5mM EGTA, 100mM MgCl2 in 0.1 M NaPO4 (pH 7.3) for 4h at 
4°C with one solution change. The samples were transferred to 15% sucrose in 
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PBS for 4h and subsequently to 30% sucrose in PBS at 4°C overnight. Samples 
were embedded in Tissue-Tek O.C.T. and 15µm sections were cut. The sections 
were dried at RT for 2h before staining. For staining, the sections were washed 
twice with PBS and the X-GAL staining solution was incubated overnight at 37°C. 
Counterstain was performed with hemalaun. 
Western blot analysis 
Cells were harvested, lysed in extraction buffer [20 mM Tris-Cl, 150 mM NaCl, 1 
mM EDTA, 1 mM EGTA, 1 % (v/v) Triton X-100, supplemented with CompleteTM 
Proteinase Inhibitor Cocktail (Merck Biosciences)]. Protein extracts were clarified 
by centrifugation (6,000 × g) at 4 °C. Protein concentrations were determined 
using the method of Bradford and 25 µg of total protein was separated on 10% 
SDS-polyacrylamide gels. Separated proteins were transferred onto nitrocellulose 
membranes (Invitrogen), the membranes were blocked with 5% non-fat dry milk 
in TBS, and incubated with the indicated primary antibodies. After washing, 
membranes were incubated with appropriate secondary, horseradish peroxidase-
linked antibodies (Pierce). Proteins were visualized by enhanced 
chemiluminescence and autoradiography (ECL, Amersham Biosciences).  
Proliferation assay 
Primary ATII cells were plated at a density of 15 × 104/well in 48-well plates, 
synchronized for 24 h in serum-free medium, and treated for 24 h as indicated. 
Primary mouse fibroblasts or human lung fibroblasts (HFL1) cells were seeded at 
a density of 15 × 103/well and synchronized for 24 h in serum-free medium. 3H-
thymidine (0.5 µCi/ml; Amersham Biosciences, Piscataway, NJ) was added to the 
media for the last 6 h of each experiment. Cells were then washed 3× with PBS, 
lysed in 10% trichloroacetic acid, and incorporation of 3H-thymidine was 
determined by liquid-scintillation counting. In addition, proliferation was assessed 
by cell counting 24 h after stimulation with WISP1, each condition counted at 
least three times. 
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Migration assay 
Cell migration was determined using a Boyden chamber assay (ThinCertsTM 
Tissue Culture Inserts, 24 wells, pore size 3.0 μm, from Greiner Bio-One) (54). 
Cells were cultured for 24h to allow their attachment to the membrane, serum 
starved, and migration was induced by adding either WISP1 or TGF-β1 to the 
media in the lower wells, as indicated. After 24 h, cells were fixed and stained 
using crystal violet solution (Sigma-Aldrich), and non-migrated cells were 
removed by cotton swabbing. The number of migrated cells at the bottom of the 
filter was counted under a light microscope. 
Collagen assay 
 NIH-3T3 cells or human lung fibroblasts (HFL1) were plated at a density of 
30,000 cells/well in 6-well plates, synchronized for 24 h in serum-free medium, 
and treated for 24 h as indicated. Whole lung homogenates were used for in vivo 
analysis. Total collagen content was determined using the Sircol Collagen Assay 
kit (Biocolor). Equal amounts of protein lysates were added to 1 ml of Sircol dye 
reagent, followed by 30 min of mixing. After centrifugation at 10,000 × g for 10 
min, the supernatant was carefully aspirated and 1 ml of alkali reagent was 
added. Samples and collagen standards were then read at 540 nm in a 
spectrophotometer (Bio-Rad). Collagen concentrations were calculated using a 
standard curve with acid-soluble type 1 collagen. 
Small interfering RNA (siRNA) transfection 
The siRNA duplexes targeting mouse Wisp1 mRNA were obtained from 
Dharmacon Inc (siRNA antisense si#1: 5´-uugauugaacuuauuagcctc- 3´). The 
siRNAs (150 nM) were transiently transfected into primary ATII cells using 
LipofectamineTM 2000 Reagent (Invitrogen) at a siRNA:Lipofectamine ratio of 1:2 
(μg:μl). To control for non-specific gene inhibition of the siRNAs, a negative-
control siRNA (scrambled) sequence was employed. Cells were harvested and 
analyzed on mRNA and protein level 24 h after the transfection. 
Lung function measurement 
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Anaesthetized and relaxed mice were tracheotomized, placed in a small animal 
whole body plethysmographic chamber (Buxco), and ventilated in volume-driven 
mode (with a positive end-expiratory pressure (PEEP) of 0 mmHg). Before 
measuring lung compliance, chambers were calibrated with a rapid injection of 
300 µl room air. Respiration rate was set to 20/min and ventilation pressure was 
recorded while inflating the lung at a tidal volume of 200 µl. Ventilator 
compliances are given in kPa/ml and corrected for mouse whole body weight. 
Statistical analysis 
All ΔCt values obtained from quantitative RT-PCR and all data derived from 
compliance measurements were analyzed for normal distribution using the 
Shapiro-Wilk test, with the assignment of a normal distribution with p > 0.05. 
Normality of data was confirmed using quantile-quantile plots. All ΔΔCt values 
were analyzed using the two-tailed, one-sample t-test. Intergroup differences of 
ΔCt values from patients and bleomycin-treated mice were derived using a one-
tailed, two-sample t-test. Proliferation assay data were analyzed using the 
Wilcoxon Rank sum test and the Singed Rank test. Compliance values were 
analyzed using the two-tailed, two-sample t-test. All p values obtained from 
multiple tests were adjusted using the procedure from Benjamini & Hochberg. All 
results presented as mean ± s.e.m., if not otherwise stated, and were considered 
statistically significant when p < 0.05 (** p < 0.02, * p < 0.05). 
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RESULTS 
 
Enhanced ATII cell proliferation in experimental lung fibrosis 
We initially characterized primary ATII cells in lung fibrosis by investigating the 
morphology and proliferative capacity of freshly isolated ATII cells from mice 
subjected to bleomycin-induced lung fibrosis, as well as from time-matched, 
saline-treated control mice. A similar purity was observed when isolating ATII 
cells from control or bleomycin-treated mouse lungs [95 ± 3% of pro-surfactant 
protein C (SPC)-positive and α-smooth muscle actin (αSMA)-negative cells] 
(Figure 1).  
 
Figure 1. The purity of ATII cell isolations from saline- or bleomycin-treated mice, 14 days after 
instillation, as indicated, was analyzed by immunofluorescent staining. ATII cells were fixed 
directly after isolation (cytocentrifuge preparations) and stained with antibodies against the ATII 
cell marker pro-surfactant protein C (SPC; magnification: 40×, size bar = 10µm), or the (myo)-
fibroblast marker αSMA (inlets, magnification: 10×). 
 
 
Morphological analysis revealed the expression of the epithelial marker proteins 
SPC, tight junction protein (TJP) 1, e-cadherin (ECAD), as well as occludin 
(OCLN) (Figure 2, for secondary antibody controls see Figure S1) in both cell 
isolations. 
saline bleo 
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Figure 2. The phenotype of ATII cell isolations from saline- or bleomycin-treated mice, 14 days 
after instillation, as indicated, was analyzed by immunofluorescent staining. ATII cells were fixed 
after 24h of attachment and subsequently stained with antibodies against SPC, tight junction 
protein (TJP) 1, e-Cadherin (ECAD), or occludin (OCLN), as indicated (magnification 40×). 
 
SPC TJP1 
ECAD OCLN 
saline 
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ATII cells isolated from the lungs of bleomycin-treated mice, however, 
demonstrated a significant increase in cell proliferation, as assessed by Ki67 
staining and [3H]-thymidine incorporation (186 - 225% of control ATII cells, 95% 
C.I.) (Figure 3A, B). In accordance with these observations, ATII cells from 
bleomycin-treated mice exhibited increased mRNA levels of the proliferation 
markers Ki67, Cyclin G1, and Cyclin B2, when compared to time-matched, 
saline-treated mice (Figure 4).  
 
 
Figure 3. (A) Double immunostaining for panCK (green) and KI67 (red) was performed in primary 
ATII cells from saline- or bleomycin-treated mice, 14 days after instillation (magnification 40×). 
Nuclei were visualized by DAPI staining (inlet). All stainings are representative of at least three 
independent experiments. (B) ATII cell proliferation was analyzed in primary cells isolated from 
mice 7 or 14 d after instillation with bleomycin, as indicated, by [3H]-thymidine incorporation. Data 
are presented as fold-change of [3H]-thymidine incorporation compared with saline-instilled 
controls by box- and whisker plots (n = 10 per group). 
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Figure 4. The mRNA levels of the proliferation markers Ki67, Cyclin G1, or Cyclin B2 were 
analyzed by quantitative (q)RT-PCR using primary ATII cells and plotted as log-fold increase 
(ΔΔCt) of mRNA levels in bleomycin- vs. saline-treated mice, 14 days after instillation (n = 6 
each). Results are presented as mean ± s.e.m., * p<0.05, ** p<0.02. 
 
Whole genome expression profiling of ATII cells in experimental lung 
fibrosis 
To uncover potential gene regulatory networks driving increased ATII cell 
proliferation, we next performed whole genome microarray analysis comparing 
gene signatures of freshly isolated ATII cells from bleomycin- with saline-instilled 
mice. As depicted in Figure 5, several gene families were differentially expressed 
in ATII cells obtained from fibrotic lungs. In accordance with our initial 
observations, ATII cells isolated from fibrotic mouse lungs demonstrated a 
remarkable upregulation of proliferative mediators and/or markers, such as 
oncogenes and cell cycle-associated genes. Furthermore, the ATII cell gene 
expression profile also indicated an enrichment of inflammatory stimuli and pro-
inflammatory cytokines in experimental lung fibrosis, suggesting that, at least in 
the mouse, this is part of the alveolar epithelial cell response to fibrogenic stimuli.  
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Figure 5. (A) ATII cell gene expression profiles were analyzed by whole genome expression 
analysis using RNA from freshly isolated ATII cells from saline- or bleomycin-treated mouse lungs 
14 d after administration. Red and green indicate increased and decreased gene expression 
levels, respectively, in ATII cells isolated from bleomycin- vs. saline-treated mice. Columns 
represent individual samples, including dye-swap experiments. Selected genes are represented 
in rows. (B) Functional annotation of regulated gene clusters was performed according to Gene 
Ontology (GO) or the Kyoto Encyclopedia of Genes and Genomes (KEGG), as indicated. 
 
 
Differentially expressed transcripts also included genes that have previously 
been reported to be upregulated in bleomycin-induced lung fibrosis and IPF, 
including Spp1 (55, 56), Timp1 (57), Sfrp1(58), and Pai1 (59). 
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To confirm these findings, the gene expression profiles were further investigated 
in an independent set of freshly isolated, and short term cultured (48h) ATII cells 
by quantitative (q)RT-PCR (Figure 6), essentially giving consistent gene 
regulatory findings.  
 
 
Figure 6. Confirmation of microarray results was performed for selected genes in freshly isolated 
ATII cells (n = 6), as well as in ATII cells 72 h after isolation (n = 3) by qRT-PCR, as indicated. 
Following genes were analyzed: secreted frizzled-related protein (Sfrp) 1, inhibin beta A (Inhba), 
found in inflammatory zone (Fizz) 1, secreted phosphoprotein (Spp) 1, WNT1-inducible signalling 
pathway protein (Wisp) 1, cadherin (Cdh) 16, and potassium voltage-gated channel subfamily E 
member (Kcne) 2. Results are presented as mean ± s.e.m., **p<0.02 for all bars, compared with 
ATII cells isolated from saline-treated mice. 
 
Of interest, the expression of genes of the WNT signalling pathway (Wnt10a, 
Sfrp1, Tcf4, Cyclin D1) was upregulated in ATII cells during bleomycin-induced 
lung fibrosis. In particular, expression of the WNT1 inducible signalling protein 
(Wisp) 1, a member of the recently described CCN family of secreted signalling 
molecules (60, 61), was highly upregulated.  
The WNT family of highly conserved secreted growth factors is essential to organ 
development and known to determine epithelial cell fate (62, 63).  The canonical 
WNT signalling pathway, or β-catenin-dependent pathway, regulates gene 
transcription by stabilization of β-catenin. Upon WNT stimulation, receptor 
activation leads to glycogen synthase kinase (GSK)-3β phosphorylation, thereby 
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preventing β-catenin phosphorylation by GSK-3β. As a result, β-catenin 
accumulates, translocates to the nucleus, and regulates target gene expression 
via interaction with the T-cell-specific transcription factors (TCF) (62, 63) (Figure 
7).  
 
 
 
Figure 7. Canonical WNT signalling scheme.  
 
 
Increased expression of WNT/β-catenin signalling molecules in lung 
epithelial cells during experimental lung fibrosis 
To further elucidate, whether WNT/β-catenin activation is an early event in 
experimental lung fibrosis, as indicated by our initial gene expression analysis, 
we sought to quantify the mRNA expression of canonical WNT/β-catenin 
signalling components in ATII cells isolated from the lungs of bleomycin or saline-
treated mice. The investigated WNT ligands were variably expressed in ATII 
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cells, and Wnt1, Wnt2, Wnt7b and Wnt10b mRNA levels were markedly 
upregulated, whereas Wnt3a was significantly downregulated (Figure 8). The 
common WNT receptors frizzled (Fzd), as well as the intracellular signal 
transducers Gsk-3β, β-catenin, and Tcf4 were expressed in ATII cells, with a 
relative high abundance of β-catenin. Fzd1 and Gsk-3β were significantly 
upregulated in ATII cells of bleomycin-treated mice (Figure 9).  
 
Figure 8. The mRNA levels of the WNT target gene Mmp7, the WNT ligands Wnt1, Wnt2, Wnt3a, 
Wnt7b, and Wnt10b were assessed in ATII cells isolated from bleomycin- and saline-treated mice 
(n = 6 each) by qRT-PCR. Results are presented as mean ± s.e.m., * p<0.05, ** p<0.02, as 
indicated. 
 
 
Figure 9. The mRNA levels of the receptors frizzled (Fzd) 1, 2, 4, and the intracellular signal 
transducers Gsk-3β, β-catenin, and Tcf4 were assessed in ATII cells isolated from bleomycin- 
and saline-treated mice (n = 6 each) by qRT-PCR. Results are presented as mean ± s.e.m., * 
p<0.05, ** p<0.02, as indicated. 
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Active WNT/β-catenin signalling in vivo during the development of 
experimental lung fibrosis 
TOPGAL reporter mice were used next to localize the activation of the WNT/β-
catenin pathway in vivo in experimental lung fibrosis. The detailed treatment 
scheme is outlined in Figure 10.  
 
 
Figure 10. Treatment scheme of TOPGAL mice. Recombinant mouse WNT3A or vehicle control 
was administered orotracheally (500 ng or 1000 ng in 80µl total volume) and mouse lungs were 
excised after 24h for the detection of β-galactosidase in the challenged TOPGAL mice. In a 
second arm, TOPGAL reporter mice were challenged with Bleomycin or saline as described in 
detail in Material & Methods and analyzed on different time points, as indicated. At least four mice 
per time point were analyzed. 
 
Mice were treated orotracheally with either recombinant WNT3A to demonstrate 
the capability of the lung to activate WNT/β-catenin signalling (Figure 11, upper 
panel), or bleomycin to induce lung fibrosis (Figure 11, lower panel). As depicted, 
bronchial and alveolar epithelial cells routinely stained for β-galactosidase (β-
GAL), in response to WNT3A or bleomycin. Examination of mouse lungs 
harvested at different time points after a single administration of bleomycin 
revealed an activation of WNT/β-catenin signalling as early as 5 days after the 
initial injury, with distinct bronchial and alveolar epithelial cells responding to 
WNT activation (Figure 11). 
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Figure 11. TOPGAL reporter mouse were treated orotracheally with WNT3A or bleomycin, as 
described in detail in Material & Methods. The X-GAL staining of β-galactosidase activity in lungs 
from WNT3A- and vehicle- treated mice (A, upper panel), or bleomycin- and saline-treated mice 
(A, lower panel) were performed. Pictures are representative of at least two independent 
experiments using at least four different lung tissues for each condition, the magnifications are 
indicated by scale bars. 
 
The epithelial nature of cells with active WNT signalling was further confirmed by 
colocalization of β-GAL and the ATII cell marker SPC, or the clara cell specific 
protein (CCSP), respectively (Figure 12).  
 
 
Figure 12. β-GAL, SPC, and clara cell specific protein (CCSP) protein expression in serial whole 
lung sections from bleomycin-treated TOPGAL reporter mouse was assessed by 
immunohistochemistry, the magnification is are indicated by the scale bar. 
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Increased expression of the WNT target genes Cyclin D1 and Wisp1 upon 
WNT3A stimulation in primary ATII cells in vitro further confirmed these results 
(Figure 13). 
 
 
Figure 13. Primary ATII cells were stimulated with WNT3A (100 ng/ml) and the mRNA levels of 
Ctgf, Wisp1, and Cyclin D1 were analyzed by qRT-PCR (n = 4 for each) at the indicated time 
points and plotted as log-fold increase (ΔΔCt) of mRNA levels in WNT-stimulated vs. unstimulated 
cells. Results are presented as mean ± s.e.m., * p<0.05, ** p<0.02.  
 
 
Increased expression of WISP1 in ATII cells in vitro and in vivo in 
experimental pulmonary fibrosis  
Based on the evidences, that 1) the WNT target WISP1 was one of the most 
regulated genes in ATII cells isolated from fibrotic mouse lungs, and 2), active 
WNT signalling is present in lung fibrosis, we continued our further studies on 
WISP1 as a potential novel mediator and amenable therapeutic target. WISP1 is 
a member of the CCN family of matricellular proteins, which consist of 
CYR61/CCN1, CTGF/CCN2, NOV/CCN3, WISP1/CCN4, WISP2/CCN5, 
WISP3/CCN6 (60, 64, 65). CCN proteins are comprised of four conserved 
cysteine-rich modular proteins. They act trough binding to specific integrin 
receptors and heparin sulfate proteoglycans, or modulate the activities of other 
growth factors and cytokines, thereby triggering a variety of cell functions, such 
as mitosis, adhesion, and migration of multiple cell types (64) (Figure 14). CCN 
family members were associated with different developmental and disease 
processes, however, little is known about WISP1 and WISP2.  
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Figure 14. The CCN protein family (66).  
 
We next analyzed the expression of all CCN family members in vivo in mice 
subjected to bleomycin-induced lung fibrosis. Of all six CCN family members, 
Wisp1 mRNA exhibited the highest fold-induction in lung homogenates during 
bleomycin-induced lung fibrosis (Figure 15).  
 
Figure 15. A time-course for CCN family member gene expression was performed using qRT-
PCR of lung homogenates harvested 7, 14, or 21 d after administration of bleomycin. Respective 
mRNA levels were plotted as log-fold change (ΔΔCt) of mRNA levels in bleomycin- vs. time-
matched saline-treated mice (n = 4), and presented as mean ± s.e.m., * p<0.05, ** p<0.02. 
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Furthermore, WISP1 protein localized to ATII cells in vivo as documented by 
immunohistochemistry and increased expression thereof in lung homogenates 
was demonstrated by Western blot analysis (Figure 16). 
 
 
Figure 16. (A) WISP1 protein expression was assessed using immunohistochemical staining of 
whole lung sections of bleomycin- or saline-treated mice 14 d after application (upper panel, 
magnification as indicated) and (B) Western blot analysis in total protein lysates (lower panel). 
Recombinant mouse WISP1 protein served as a positive control, β-Actin served as a loading 
control. Data are representative of at least two independent experiments using six (saline) or five 
(bleo) different lung tissues each. 
 
In support, Wisp1 mRNA exhibit the highest fold-regulation of all CCN family 
members in isolated ATII cells, but not primary fibroblasts, isolated from 
bleomycin-treated mouse lungs (Figure 17), underlining that WISP1 originates 
from ATII cells during lung fibrosis. WISP1 expression was increased at the 
protein level in isolated ATII cells, as documented by co-immunofluorescence 
staining of WISP1 and ECAD (Figure 18).  
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Figure 17. The mRNA levels of all CCN family members were determined by qRT-PCR in 
primary ATII cells (black bars, n = 6) or primary fibroblasts (open bars, n = 4) isolated from the 
lungs of saline- or bleomycin-treated mice 14 d after administration. Results are plotted as log-
fold change (ΔΔCt) of mRNA levels in bleomycin-derived vs. saline-derived cells, and presented 
as mean ± s.e.m., * p<0.05, ** p<0.02. 
 
 
 
Figure 18. WISP1 protein expression was assessed using double immunostaining for ECAD 
(green) and WISP1 (red) of primary ATII cells from saline- or bleomycin-treated mice, respectively 
(magnification 40×). Nuclei were visualized by DAPI staining (inlet). Data are representative for at 
least three independent experiments. 
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Increased expression of WISP1 in ATII cells in vitro and in vivo in idiopathic 
pulmonary fibrosis (IPF) 
We next sought to investigate whether increased WISP1 expression was also 
evident in human lung tissues derived from IPF patients. To this extent, we 
analyzed the mRNA levels of all CCN family members in lung specimen obtained 
from IPF (UIP pattern) or control (transplant donors) patients. With the exception 
of WISP3, all CCN family members were expressed in human lungs (Figure 19). 
WISP1 demonstrated the lowest overall lung mRNA expression, but the highest 
relative differences comparing IPF with donor lung homogenates. 
 
Figure 19. The mRNA levels of the CCN family members were analyzed by qRT-PCR using lung 
homogenates derived from donor or IPF lung explants (n = 10 each), as indicated. 
 
Furthermore, increased expression of WISP1 mRNA was detectable in laser-
assisted microdissected septae obtained from IPF and donor lungs (Figure 20A). 
The qRT-PCR analysis of primary human ATII cells and fibroblasts further 
revealed that WISP1, and to a lesser extent connective tissue growth factor 
(CTGF), was highly upregulated in ATII cells, but not in primary fibroblasts 
obtained from IPF patients (Figure 20B). 
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Figure 20. (A) The mRNA levels of Wisp1 and Ctgf were analyzed by qRT-PCR in 
microdissected septae from donor or IPF lungs (n = 5 each). Results are plotted as relative 
mRNA levels (ΔCt) and presented as mean ± s.e.m., * p<0.05, ** p<0.02. (B) The mRNA levels of 
Wisp1 (open bars) and Ctgf (black bars) were determined by qRT-PCR in primary human ATII 
cells (n = 4) or fibroblasts (n = 3) isolated from donor or IPF lung tissue, as indicated. Results are 
plotted as log-fold increase (ΔΔCt) of mRNA levels in IPF-derived vs. donor-derived cells and 
presented as mean ± s.e.m., * p<0.05 
 
Consistently, WISP1 localized to hyperplastic, proliferating ATII cells in close 
proximity to epithelial lesions and fibroblast foci in IPF (Figure 21, for antibody 
control see Figure S2), as assessed by staining of WISP1 and phospho-histone 
H3 in serial sections. WISP1 protein expression was increased in tissue samples 
from IPF patients, as determined by Western Blot analysis (Figure 22A). 
Importantly, increased expression of WISP1 was specific for IPF, whereas in 
other lung disorders, such as non specific interstitial pneumonia (NSIP) or 
chronic obstructive pulmonary disease (COPD), no regulation of WISP1 mRNA 
was observed (Figure 22B). 
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Figure 21. WISP1 protein expression in sections from control or IPF lung specimen was 
assessed by immunohistochemistry, the magnification is indicated by the scale bars. Arrows point 
to extracellular WISP1 staining. WISP1 and Phospho-Histone 3 (H3) protein expression in serial 
whole lung sections from IPF patients (right panel). Data are representative of at least two 
independent experiments using at least four different lung tissues from IPF specimens. 
 
 
Figure 22. (A) WISP1 protein expression was determined in total protein lysates from donor or 
IPF lung tissue by Western blotting. Lamin A/C was used as a loading control. Data are 
representative of at least two independent experiments using six different lung tissues for donors 
and IPF. (B) The mRNA levels of Wisp1 were analyzed by qRT-PCR using lung homogenates 
derived from IPF (n = 6), NSIP (n = 4) or COPD (n = 6) lung explants, as indicated. Results are 
plotted as log-fold increase (ΔΔCt), compared with control lungs (transplant donor), and 
presented as mean ± s.e.m., * p<0.05, ** p<0.02. 
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Increased ATII cell proliferation and profibrotic marker release in response 
to WISP1 
To begin to delineate the functional contribution of WISP1, the effect of 
recombinant WISP1 on ATII cells was assessed next. WISP1 treatment exerted a 
strong proliferative effect on primary ATII cells (Figure 23 and 24, 154 - 220%, 
95% C.I.), which was more pronounced than that of CTGF or keratinocyte growth 
factor (KGF) (Figure 24A). In contrast, ATII cells obtained from bleomycin-treated 
animals were not responsive to WISP1 stimulation (bleo: 186 - 213% vs. bleo + 
WISP1: 199 - 215%) (Figure 24A).  
 
Figure 23. The effect of WISP1 (1 µg/ml, 24 hrs) on the proliferation of primary ATII cells was 
assessed by co-immunostaining of Ki67 (red) and TJP1 (green) (magnification 40×). Nuclei were 
visualized by DAPI staining (blue). 
 
 
Since these cells secreted higher amounts of WISP1 (Figure 16-18), thereby 
driving a proliferative response, we sought to neutralize WISP1 using two 
different approaches: As depicted in Figure 24B, WISP1 antagonism using 
neutralizing antibodies attenuated the increased baseline proliferation of fibrotic 
ATII cells (bleo + αWISP1: 103 - 148%). 
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Figure 24. (A) The effects of WISP1 (1 µg/ml), CTGF (2.5 ng/ml), or KGF (10 ng/ml) on primary 
mouse ATII cell proliferation were assessed by [3H]-thymidine. (B) The effects of neutralizing 
αWISP1 antibodies (20 µg/ml αWISP1) or pre-immune serum (IgG control), each applied 30 min 
prior to the addition of WISP1, was analyzed. Data are presented as relative proliferation, 
compared with unstimulated ATII cells isolated from saline-treated mice (n = 10 upper panel, n = 
5 lower panel), ** p<0.02 vs. control, # p<0.02 vs. WISP1 stimulation, ## p<0.02 vs. control bleo. 
 
Second, these results were confirmed using small interfering (si)RNA against 
Wisp1 (Figure 25). The mRNA and protein knockdown efficiency is depicted in 
Figure 25 A and B. The knockdown of Wisp1 led to decreased proliferation of 
primary ATII cells isolated from bleomycin- and saline-treated mouse lungs, as 
analyzed by cell counting (Figure 25C) and [3H]-thymidine incorporation (Figure 
25D), respectively. 
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Figure 25. The Wisp1 knockdown was analyzed by qRT-PCR (A) and Western Blot (B). Two 
different siRNA sequences were tested in different concentrations, as indicated. Cells were 
harvested and lysed 24 h after transfection. For all further experiments si #1 (150 nm) was used., 
(C, D) Proliferation of ATII cells subjected to scrambled (scr) or Wisp1 siRNA (siW1) treatment 
(150 nM each) was assessed by cell counting 24 h after treatment (C)or 3H-thymidine 
incorporation (D). ** p<0.02 bleo vs. saline, # p<0.02 siRNA vs. scrambled.  
 
 
Epithelial-to-mesenchymal transition (EMT) in response to WISP1 
EMT is the reversible phenotypic switching of epithelial to fibroblast-like cells, and 
has recently gained recognition as a possible mechanism that increases the 
(myo)-fibroblast pool in pulmonary fibrosis (67, 68). It has been demonstrated 
that TGF-β represents a main inducer and regulator of EMT in multiple organ 
systems (38, 39), but little is known about other cytokines or mediators that are 
able to induce EMT during lung fibrosis. Here, we show that WISP1 treatment of 
primary ATII cells led to decreased mRNA levels of Tjp1, eCad and Occl, but 
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elevated mRNA levels of Fsp1 and αSMA, as analyzed by qRT-PCR, indicating 
that WISP1 is a potent inducer of EMT in ATII cells in vitro (Figure 26).  
 
Figure 26. Primary mouse ATII cells were stimulated with WISP1 (1 µg/ml, 12 h) and the mRNA 
levels of the EMT marker genes eCad, Tjp1, Occl, Fsp1, Vim, and αSMA were analyzed by qRT-
PCR (n = 5 for each). All qRT-PCR results are presented as mean ± s.e.m., ** p<0.02, * p<0.05. 
 
The induction of EMT was corroborated by immunofluorescent staining, revealing 
an increase in αSMA positive cells (Figure 27, left panel), as well as αSMA and 
TJP1 double-positive cells (middle panel) in response to WISP1. This was 
abrogated by neutralizing antibodies against WISP1 (right panel).  
 
Figure 27. Primary ATII cells were stimulated with WISP1 (1 µg/ml, 12 h) in the absence or 
presence of neutralizing αWISP1 antibodies or pre-immune serum (IgG control), as indicated. 
EMT was assessed by immunofluorescent detection of αSMA expression (left panels, original 
magnification: 10×) and co-localization of αSMA (green) and TJP1 (red) (middle and right panels, 
original magnification: 40×). Nuclei were visualized by DAPI staining. 
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Furthermore, treatment with WISP1 lead to enhanced migration of ATII cells, 
which is associated with the process of EMT (Figure 28A). WISP1 treatment of 
ATII cells rapidly induced the expression of pro-migratory genes, such as Mmp7 
and Mmp9, as well as the previously identified mediators in pulmonary fibrosis, 
such as Pai1, and Spp1 (Figure 28B). This strongly suggests that WISP1 is not 
only causally involved in ATII cell hyperplasia, but also induces increased 
expression and secretion of profibrotic mediators, thereby further perpetuating 
the process of lung fibrosis. Finally, the potential of ATII cells to undergo EMT in 
vivo was supported by qRT-PCR analysis of freshly isolated ATII cells, which 
revealed a gain of mesenchymal marker expression and a loss in epithelial cell 
marker expression in ATII cells isolated from fibrotic mouse lungs (Figure 28C).  
 
 
Figure 28. (A) The migration of ATII cells in response to WISP1 was determined in a Boyden 
Chamber assay, TGF-β1 (2 ng/ml) was used as a positive control. Data are presented as the 
mean ± s.e.m. (n = 6). (B) Primary ATII cells were stimulated with WISP1 (1 µg/ml, 12 h) and the 
mRNA levels of Mmp2, Mmp7, Mmp9, and Pai1 and Spp1 were analyzed by qRT-PCR (n = 5 
each). (C) The mRNA levels of the EMT marker genes eCad, Tjp1, Occl, Fsp1, Vim, and αSMA 
were determined by qRT-PCR in primary ATII cells isolated from saline- or bleomycin-treated 
mice 14 d after administration (n = 6).  
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Attenuation of lung fibrosis in vivo by WISP1 inhibition 
To assess whether modulation of WISP1 activity represented an effective 
therapeutic option in lung fibrosis, we depleted WISP1 during bleomycin-induced 
lung fibrosis using antibodies shown to be effective in neutralizing WISP1 activity 
(Figure 24 and 27). To this extent, mice were subjected to bleomycin-induced 
lung fibrosis, and treated with repetitive orotracheal applications of αWISP1, or 
species-matched pre-immune control antibodies. Mice subjected to WISP1 
neutralization exhibited significantly less pulmonary fibrosis and a marked 
decrease in ECM deposition, as assessed by quantification of total lung collagen 
(bleo + IgG: 295 ± 17% vs. bleo + αWISP1: 160 ± 31%, compared with saline-
treated controls) (Figure 29), immunohistochemistry for type 1 collagen (Figure 
30), as well as αSMA immunostaining (Figure 31). 
 
Figure 29. Total collagen content in lung homogenates was quantified using the Sircol collagen 
assay. Results are derived from whole lungs harvested 14 days after saline, bleomycin, 
bleomycin plus pre-immune serum (IgG control), or bleomycin plus neutralizing αWISP1 antibody 
instillation by orotracheal application, as indicated (n = 5 each). Results are presented as mean 
±.s.e.m., ** p<0.02, # p<0.02 vs. bleo + IgG. 
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Figure 30. Mice were subjected to saline or bleomycin instillation, as described before, and 
treated either with neutralizing αWISP1 antibodies or pre-immune serum (IgG control) by 
orotracheal application as described in detail in Material & Methods. Lungs were processed 14 d 
after bleomycin application for immunohistochemical analysis and stained for type I collagen. 
 
 
bleo 
bleo + αWISP1 bleo + IgG 
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Figure 31. Indicated lung sections were used for immunohistochemical analysis and stained with 
αSMA. Pictures are representative of at least two independent experiments using at least four 
different lung tissues for each condition. 
 
These findings were corroborated by the fact that WISP1 neutralization also led 
to decreased mRNA expression of the profibrotic markers Col1a1, Spp1, Mmp7, 
and Pai1 (Figure 32A), which is of significance as we have shown that WISP1 
induces the expression of these markers in primary ATII cells (Figure 28B). In 
addition, WISP1 neutralization resulted in a reversal of EMT marker gene 
expression in vivo (Figure 32B), which were induced by WISP1 in vitro (Figure 
26).  
bleo + IgG bleo + αWISP1 
bleo saline 
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Figure 32. The mRNA levels of the profibrotic marker genes Col1a1, Spp1, Mmp7, Pai1, and Ctgf 
(A), and the EMT marker genes Tjp1, eCad, Occl, Fsp1, Vim, and αSMA (B) were analyzed by 
qRT-PCR (n = 5 each). Results are plotted as log-fold change (ΔΔCt) of mRNA levels in lung 
specimens 14 days after bleomycin instillation treated with neutralizing αWISP1 antibodies, 
compared with lungs treated with pre-immune serum (IgG control). Results are presented as 
mean ± s.e.m., * p < 0.05, ** p<0.02, # p<0.02 vs. bleo + IgG treatment. See Figure S6A and S6B 
in the supplementary material for a comparison of all treatment groups. 
 
 
Finally, WISP1 neutralization partially restored normal lung function, as assessed 
by lung compliance measurements (bleo ± IgG: 0.065 ± 0.073 ml/kPa vs. bleo ± 
αWISP1: 0.09 ± 0.11 ml/kPa, 95% C.I., Figure 33A). Most importantly, WISP1 
neutralization significantly improved the survival of bleomycin-challenged mice 
(bleo + IgG: 47% vs. bleo + αWISP1: 74%, n =18 for each) (Figure 33B), 
presenting as a valuable novel approach for the treatment of lung fibrosis. 
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Figure 33. (A) Lung compliance measurements were obtained from mice instilled with saline, 
bleomycin, bleomycin plus IgG control, or bleomycin plus αWISP1 antibody (n = 10 for each), 14 
d after initial exposure to bleomycin. *p<0.05, **p<0.02, # p<0.02 vs. bleo + IgG treatment. (B) 
The survival of mice subjected to neutralizing αWISP1 or pre-immune serum (IgG control) 
instillations (n = 18 for each) was monitored. Days of antibody instillations are indicated on the x-
axis, **p<0.02.  
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DISCUSSION 
In the current study, we report that WISP1, a member of the CCN family of 
secreted cysteine-rich matricellular proteins, represents a novel mediator of 
impaired epithelial-mesenchymal crosstalk in lung fibrosis and a suitable 
therapeutic target in this disease. We demonstrated that WISP1 was highly 
expressed in hyperplastic ATII cells, mediated enhanced ATII cell proliferation, 
and induced profibrotic marker gene expression in ATII cells. In addition, WISP1 
enhanced fibrogenesis by inducing EMT of ATII cells, indicating that WISP1 
exerts its profibrotic effects by a multitude of effects in the lung (Figure 36). Most 
importantly, neutralization of WISP1 resulted in marked attenuation of bleomycin-
induced lung fibrosis.  
These findings are of special interest, as IPF exhibits a poor prognosis due to 
unresponsiveness to currently available therapies. IPF is the most common form 
of idiopathic interstitial pneumonias (IIP), which all exhibit distortion of normal 
tissue architecture and a loss of lung function (1, 69). This fibrotic tissue 
transformation is characterized by an increase in total lung collagen levels with 
the inability of the lung to properly conduct gas exchange. While historically, 
inflammatory processes were thought to trigger and facilitate the progression of 
IPF (69, 70), this view has recently been questioned, primarily due to the 
ineffectiveness of anti-inflammatory therapy in IPF (28, 71). A major key 
pathophysiological event in IPF that is currently discussed includes repetitive 
alveolar epithelial cell injury and stimulation without appropriate repair and 
subsequent fibroblast activation (28, 72). 
 
Alveolar epithelial cell proliferation in IPF 
At the onset of our studies, we sought to define alterations in the phenotype and 
gene expression profile of ATII cells that may initiate and perpetuate the 
progression of lung fibrosis. The findings that ATII cells from fibrotic lungs 
exhibited an increased proliferative capacity and enhanced gene expression of 
proliferative mediators indicated to us that ATII cell proliferation is a dominant 
pathophysiologic mechanism after initial injury in experimental lung fibrosis. 
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Indeed, injury and apoptosis within the alveolar epithelium, with subsequent ATII 
cell hyperplasia, are consistent findings in experimental and human lung fibrosis. 
In human lung biopsies, nascent fibrotic foci colocalize with unrepaired or 
abnormal epithelia (73). In addition, experimental delay of epithelial repair in 
animal models of lung injury facilitates subsequent fibrogenesis (74).  
Several studies reported epithelial apoptosis occuring in experimental lung 
fibrosis (75-77) and human IPF lungs (78-81). Exogenous induction of epithelial 
apoptosis, e.g. by intratracheal application of Fas ligand, has been reported to 
lead to lung fibrosis (82). Moreover, inhibition of epithelial apoptosis attenuated 
experimental lung fibrosis (77). Causality between apoptosis and the fibrogenic 
process, however, still remains unclear (30, 83). Most interestingly, epithelial 
hyperplasia and proliferation is reported as well in both experimental lung fibrosis 
(84, 85) and IPF (86, 87, 88). Ultrastructural studies have revealed the existence 
of proliferative alveolar epithelial cells immediately adjacent to injured epithelial 
cells (89-91), suggesting that epithelial apoptosis and proliferation and 
hyperplasia occur simultaneously during the process of fibrosis. It is, however, 
unclear whether increased apoptosis and/or proliferation of ATII cells represent 
the initial trigger for enhanced ECM deposition in lung fibrosis (28, 29, 86). 
With respect to the finding of hyperplastic, proliferating alveolar epithelial cells in 
pulmonary fibrosis, it has to be highlighted that an increased incidence of lung 
cancer in IPF suggests a link between epithelial cell hyperplasia, impaired repair, 
and carcinogenesis (92-94).  
 
The WNT target WISP1 in IPF 
One of the most important decisions following a microarray screen of diseased 
tissues/cells is the choice of the gene of interest for functional intervention 
studies. Of all genes differentially expressed in fibrotic ATII cells, we focused our 
study on further delineating WISP1 function in lung fibrosis for the following 
reasons: 
First, WISP1 is reported to be a WNT target and WNT signalling is essential to 
organ development, a process that is recapitulated in organ failure (62, 87, 95, 
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96). Several WNT ligands, receptors, and components of the canonical pathway 
are expressed in a highly cell-specific fashion in the developing lung. For 
instance, WNT2 is highly expressed in the distal mesenchyme (97), while WNT7b 
is expressed predominantly in the epithelium (98). In addition, WNT5a is 
expressed in both cell types (99). Active WNT signalling in lung development has 
also been demonstrated using transgenic WNT reporter mice and nuclear β-
catenin staining. TOPGAL or BATGAL mice, both of which harbor a β-
galactosidase gene under the control of a LEF/TCF inducible promoter fragment, 
revealed active canonical WNT signalling early throughout the epithelium and the 
mesenchyme adjacent to proximal airways at E10.5 - 12.5, which disappeared 
first in the mesenchyme and was subsequently reduced in the epithelium at 
E13.5 – E18.5 (100-102). Epithelial-cell specific expression of constitutively 
active β-catenin leads to epithelial cell dysplasia and ectopic differentiation of 
alveolar epithelial type II cells in the conducting airways during embryonic 
development. Postnatally, these mice exhibit air space enlargement and develop 
pulmonary tumors (102). Lung epithelial cell-specific deletion of β-catenin, in 
contrast, results in disruption of branching morphogenesis with distorted 
differentiation of the peripheral lung. The mice died neonatally due to respiratory 
failure (101). 
Second, we and others demonstrated that the WNT/β-catenin pathway is 
expressed and operative in adult lung epithelium in IPF (87, 103): Chilosi et al. 
reported nuclear localization of β-catenin in ATII cells and interstitial fibroblasts in 
IPF lungs (87), indicative of activated WNT signalling (104). In addition, we have 
recently reported that canonical WNT signalling components (including WNT 
ligands, β-catenin, or GSK-3β) localized mainly to the bronchial and alveolar 
epithelium in IPF, as observed by immunohistochemistry and gene expression 
analysis of primary human ATII cells (103). Importantly, an increased activity of 
the WNT pathway in IPF was documented by increased phosphorylation of LRP6 
and GSK-3β, which has recently been demonstrated to be a sensitive indicator of 
WNT activity in tissue sections (105, 106). 
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Third, WISP1 regulation was previously reported in microarray lists derived from 
IPF lung homogenates, indicating that WISP1 is consistently upregulated in IPF 
lung tissues from different cohorts (56, 58). Selman and colleagues have also 
identified WISP1 to be regulated in a microarray analysis comparing IPF 
specimen with hypersensitivity pneumonitis (56). Notably, Lewis et al. provided a 
comparison of the gene expression profile of up to 12 different mouse models of 
infection, allergy, and lung injury (107). The authors reported regulation of WISP1 
in the mouse model of bleomycin-induced lung fibrosis, but not in any other 
inflammatory models (107). 
Fourth, increased WISP1 expression has been shown to be causally involved in 
epithelial cell hyperplasia in breast cancer cell lines (108). Finally, recent 
evidence has suggested that WISP1 exhibited anti-apoptotic and proliferative 
effects on epithelial as well as mesenchymal cell lines (109, 110) and its mRNA 
expression is associated with non small cell lung carcinoma lung cancer (111). In 
addition, several WNT proteins are overexpressed in non small cell lung 
carcinoma, including WNT1 and WNT2, and cancer cells expressing WNT1 or 
WNT2 are resistant to apoptotic therapies (112, 113).  
 
Role of WISP1 in alveolar epithelial cell function 
In our current study, we present in vitro and in vivo evidence demonstrating that 
WISP1 acted as a proliferative mediator of ATII cells in vitro and localized to 
hyperplastic ATII cells in vivo. These data are in agreement with recent reports 
showing a proliferative effect of WISP1 on epithelial cell lines (108, 114). Further, 
these data, together with the described findings in lung carcinoma specimen, 
indicate active WNT signalling as a common molecular mechanism linking 
alveolar epithelial cell transformation and hyperplasia with fibrosis or cancer. 
Further, we could show that WISP1 acted in an autocrine fashion by increasing 
the release of profibrotic cytokines from the alveolar epithelium, including SPP1, 
MMP7, MMP9, and PAI1. In particular, MMP7 has recently been assigned a key 
role in pulmonary fibrosis and shown to be expressed in ATII cells (115, 116). In 
this study, we demonstrated that MMP7, along with SPP1, PAI1, and MMP9 
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expression is induced by WISP1, essentially suggesting that a plethora of 
profibrotic markers released from ATII cells in fibrosis is under transcriptional 
control of WISP1. MMP7 and SPP1 were one of the first genes identified in IPF 
lungs using oligonucleotide microarrays, and both proteins have been co-
localized in hyperplastic alveolar epithelial cells in IPF (55, 115). Furthermore, 
MMP7-null mice as well as SPP1-null mice developed less lung fibrosis after 
bleomycin challenge (115, 117). MMP7 is a matrix metalloprotease involved in 
multiple local inflammatory effects, which has been demonstrated to be explicitly 
upregulated in IPF compared with hypersensitive pneumonitis or chronic 
obstructive pulmonary disease (116). MMP7, along with MMP1, has been 
demonstrated to be significantly increased in plasma, serum, and 
bronchoalveolar lavage fluid from IPF patients. In combination, blood levels of 
MMP1 and MMP7 may be used to distinguish IPF from hypersensitive 
pneumonitis, thereby representing as potential peripheral blood biomarkers 
(116). 
Interestingly, MMP7 is able to cleave and thereby activate SPP1 (118). SPP1, a 
secreted glycoprotein, increases the migration and proliferation of fibroblasts and 
alveolar epithelial cells (55). SPP1-null mice exhibited an attenuated response to 
bleomycin with reduced type I collagen expression and TGF-β activity (117). 
Likewise WISP1, MMP7 and SPP1 are both β-catenin target genes (119-121), 
which further corroborate that active WNT/β-catenin signalling is involved in the 
development and progression of experimental as well as idiopathic pulmonary 
fibrosis. Our finding that WISP1 induce MMP7 and SPP1 expression, indicate a 
possible positive feedback role for WISP1, further potentiating the profibrotic 
effects triggered by WNT/β-catenin signalling. 
PAI1 is a direct TGF-β target, known to be upregulated in different models of lung 
fibrosis (122-124). TGF-β has been identified has a clear pathogenic growth 
factor in experimental and idiopathic pulmonary fibrosis (44, 68, 125-128). 
Studies in transgenic animals with a lung tissue–specific expression of TGF-β as 
well as adenoviral-mediated epithelial overexpression demonstrated that the 
presence of active TGF-β induce fibrotic alterations, increased matrix deposition, 
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and parenchymal tissue distortion. It has been demonstrated that TGF-β1 
induces PAI1 expression, which leads to an inhibition of plasminogen activation 
(122). This mechanism lead to decreased plasminogen-induced fibroblasts 
apoptosis and presents a possible role of TGF-β/PAI1 in facilitating (myo)-
fibroblast survival in fibrotic diseases (122). 
Further studies are needed to reveal the detailed interaction of WISP1 with other 
profibrotic mediators, as well as distinct signalling pathways involved in WISP1-
induced effects. In this respect, we observed the activation of the Akt kinase 
(Figure 34), which is in line with previous data demonstrating Akt activation in 
response to WISP1 (109).  
 
 
 
 
 
 
 
 
 
Figure 34. (A) Primary mouse ATII cells were stimulated with WISP1 (1 µg/ml) for the indicated 
time points. Phosphorylated and total protein of AKT and p44/42 was analyzed by Western 
Blotting. PDGF served as a positive control. 
 
 
Role of WISP1 in epithelial - mesenchymal interaction 
IPF is considered a disease of impaired epithelial-mesenchymal crosstalk (28, 
30), evidenced by the close proximity of hyperplastic and injured alveolar 
epithelial cells with fibroblast foci (27, 89). The pathological remodeling of lung 
tissue during disease pathogenesis of IPF can be dictated by direct cellular 
contact, or, as described in the study herein, the secretion of soluble mediators in 
an autocrine and/or paracrine fashion. WISP1 expression was increased in lung 
fibrosis, but its expression was exclusively regulated in alveolar epithelial cells, 
whereas neither increased mRNA nor protein expression was detectable in 
fibroblasts derived from experimental lung fibrosis or IPF lungs. Several recent 
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findings from our group, however, also support a paracrine effect of ATII cell-
derived WISP1 on interstitial fibroblasts (Figure 35). We demonstrated that 
WISP1 led to increased expression of (myo)-fibroblast activation markers and 
deposition of ECM molecules. While we did not observed an influence of WISP1 
on fibroblast proliferation, a recent publication by Colston et al. (110) 
demonstrated a proproliferative effect of WISP1 on cardiac fibroblasts, 
suggesting a role for WISP1 in the remodeling of myocardial infarction. 
 
 
 
 
 
 
 
 
 
Figure 35. (A) Human lung fibroblasts were stimulated with WISP1 (1 µg/ml; 6 or 12 h, as 
indicated), and the mRNA levels of the ECM components type I collagen α1 (Col1a1), fibronectin 
(Fn1), the (myo)-fibroblast activation markers Fsp1, αSMA, tenascin C (TenC), and Timp1 were 
analyzed by qRT-PCR (n = 3). (B) Human lung fibroblasts were stimulated with WISP1 (1 µg/ml) 
or TGF-β1 (2 ng/ml) for 24 h and total collagen content was quantified using the Sircol collagen 
assay (n = 3). This Figure is kindly provided by Monika Kramer. 
 
 
WISP in epithelial-to-mesenchymal transition (EMT) 
The hallmark lesions of IPF are fibroblast foci, which are sites featuring activated 
myofibroblasts, synthesizing and depositing a collagen-rich ECM. The number of 
smooth muscle actin-positive, activated (myo)-fibroblasts is significantly 
increased in multiple forms of pulmonary fibrosis including IPF, but their origin 
remains to be elucidated. Currently, three major theories attempt to explain the 
origin of interstitial fibroblasts. It has been demonstrated that resident pulmonary 
fibroblasts can be activated in response to fibrogenic cytokines and growth 
factors, thereby increasing the fibroblast pool via local fibroproliferation (33). In 
addition, several recent studies have shown that bone marrow-derived circulating 
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fibrocytes cells traffic to the lung during experimental lung fibrosis, and serve as 
progenitors for interstitial fibroblast (35, 36, 129). Third, it was recently proposed 
that ATII cells are capable of undergoing the process of EMT, the phenotypic, 
reversible switching of epithelial to fibroblast-like cells, which is initiated by an 
alteration of the transcriptional and proteomic profile of ATII cells (38, 39). Here, 
we report that WISP1 led to the induction of EMT by regulation of marker gene 
expression and induction of ATII cell migration. As TGF-β represents a main 
inducer of EMT in multiple organ systems (67, 68), further studies are needed to 
fully appreciate the mechanistical role of WISP1 and its connectivity to the TGF-β 
pathway in this context.  
 
Role of WISP1 in lung fibrosis 
Our study demonstrates impaired epithelial-mesenchymal crosstalk in IPF, and 
suggests that the auto- and paracrine effects of WISP1, a member of the CCN 
family of secreted, cysteine-rich regulatory proteins, can initiate and perpetuate 
the fibrotic process at the interface of ATII cells and interstitial fibroblasts in the 
lung (Figure 36). Whether WISP1 induces proliferation, EMT and/or ECM 
deposition in vivo is most probably dictated by the ATII cell microenvironment in 
disease. While an intact subepithelial ECM may facilitate proliferation, a disrupted 
and/or perturbed ECM will facilitate EMT, as recently suggested in the case of 
TGF-β (38). WISP1, a signalling molecule downstream of the WNT signalling 
pathway, has thus far not been assigned a role in pathologies of the lung. Recent 
evidence, however, suggested that the WNT pathway, which is critical during 
normal development and morphogenesis, is reactivated in IPF. Future work will 
undoubtedly shed more light on the molecular mechanisms of WISP1 signalling 
and its downstream effects in IPF, and the therapeutic options derived thereof. 
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Figure 36. The role of WISP1 in lung fibrosis. A proposed model depicting the role of 
WISP1 in lung fibrosis is shown. Initial injury leads to increased WISP1 expression by 
hyperplastic ATII cells, which sustains ATII cell hyperplasia. Fibrogenesis is then 
promoted via autocrine (lower right part) or paracrine (lower left part) effects on ATII 
cell mediator release and EMT, and/or fibroblast ECM synthesis, respectively.  
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SUPPLEMENTARY INFORMATION 
Abbreviations 
AA  Amino acid 
BAL (F) bronchoalveolar lavage (fluid) 
BSA  Bovine serum albumin 
cDNA  Complementary deoxyribonucleic acid 
CHAPS 3-[3-chloramidopropyl)dimethylammonio]-1-propanesulfonate 
DAPI  4´,6-diamidino-2-phenylindole 
DMSO  Dimethyl sulfoxide 
DTT  Dithiothreitol 
ECM  Extracellular matrix 
EDTA  Ethylendinitrilo-N,N,N´,N´,-tetra-acetate 
FITC  Fluorescein-5-isothiocyanate 
FCS  Fetal calf serum 
HEPES 2-(-4-2-hydroxyethyl)-piperazinyl-1-ethansulfonate 
HRP  Horseradish peroxidase 
Im  intramuscular 
ip  intraperitoneal 
IHC  Immunohistochemistry 
mAb  monoclonal antibody 
OD  Optical density 
PBS  Phosphate-buffered saline 
PCR  Polymerase chain reaction 
qRT-PCR Quantitative RT-PCR 
rpm  rounds per minute 
RT  room temperature 
RT-PCR Reverse transcription PCR 
SDS  Sodium dodecyl sulfate 
TEMED N,N,N',N'-tetramethyl-ethane-1,2-diamine 
WB  Western blotting 
Wt  wildtype 
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Table S1. Characteristics of IPF patients with UIP pattern. VC = vital capacity, 
TLC = total lung capacity, DLCO/VA = diffusing capacity of the lung for CO per 
unit of alveolar volume (all in % predicted), PaO2/CO2 = partial pressure of O2 /CO2 
in the arterial blood. 
 
no. diagnosis gender 
Age 
(yr) 
VC 
(%) 
DLCO/VA 
(%) 
TLC 
 (%) 
O2  
(l/min) 
PaO2 
(mmHg) 
PaCO2 
(mmHg) 
1 IPF (UIP) male 63 56% 33% 48% 3 52 33 
2 IPF (UIP) male 62 50% 26% 52% 3 49 38 
3 IPF (UIP) male 58 49% na na na na na 
4 IPF (UIP) male 65 59% 20% 42% 3 53 38 
5 IPF (UIP) male 65 59% 20% 42% 4 69 41 
6 IPF (UIP) male 43 48% 27% 51% na na na 
7 IPF (UIP) male 71 40% 24% 46% na na na 
8 IPF (UIP) male 64 59% 22% 52% 2 58 38 
9 IPF (UIP) male 60 51% 18% 49% 2 59 39 
10 IPF (UIP) male 65 51% 20% 66% 2 53 38 
11 IPF (UIP) male 44 47% 25% 55% 2 36 35 
12 IPF (UIP) female 43 40% na na 2 54 35 
13 IPF (UIP) female 42 50% 17% 58% 3 52 36 
14 IPF (UIP) female 66 29% 23% 45% 4 56 45 
15 IPF (UIP) female 62 27% na 48% 4 71 65 
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Table S2. Primer sequences and amplicon sizes for human tissues. All primer 
sets worked under identical quantitative PCR cycling conditions with similar 
efficiencies to obtain simultaneous amplification in the same run. Sequences 
were taken from GeneBank, all accession numbers are denoted. 
 
Gene Accession  Sequences (5´ Æ 3´) Length Amplicon 
for cct gca ggc tag aga agc aga 21bp 
CTGF NM001901 
rev ttt ggg agt acg gat gca ctt 21bp 
103bp 
for aaa ggc agc tca ctg aag cg 20bp 
CYR61 NM001554 
rev gca ctg gga cca tga agt tgt 21bp 
110bp 
for aag gac ccc acg aag tgt tg 20bp 
HPRT1 NM000194 
rev ggc ttt gta ttt tgc ttt tcc a  22bp 
157bp 
for ccg tca atg tga gat gct gaa 21bp 
NOV NM002514 
rev ttg gtg cgg aga cac ttt ttt 21bp 
107bp 
for gta tgt gag gac gac gcc aag 21bp 
WISP1 NM003882 
rev ggc tat gca gtt cct gtg cc 20bp 
104bp 
 
for gac atg aga ggc aca ccg aag 21bp 
WISP2 NM003881 
rev gta cat ggt gtc ggg cac ag 20bp 
94bp 
for ctc cac tct tct gct tgc tgg 21bp 
WISP3 NM003880 
rev agg cct tcc ttc agg tgt tgt 21bp 
87bp 
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Table S3. Primer sequences and amplicon sizes for mouse tissues. All primer 
sets worked under identical quantitative PCR cycling conditions with similar 
efficiencies to obtain simultaneous amplification in the same run. Sequences 
were taken from GeneBank, all accession numbers are denoted. 
 
Gene Accession  Sequences (5´ Æ 3´) Length Amplicon 
for tca aga gag caa gct cat cat tct 24bp 
β-catenin NM007614 
rev cac ctt cag cac tct gct tgt g 22bp 
115bp 
for tgc aga aag cct gca cac a 19bp 
Cdh16 NM007663 
rev tgc cgt gtt tga gtc tcc tg 20bp 
130bp 
for cca aga aga cat ccc tga agt ca 23bp 
Col1a1 NM007742 
rev tgc acg tca tcg cac aca 18bp 
128bp 
for agc ttt gtg gat acg cgg act 21bp 
Col1a2 NM007743 
rev tcg tac tga tcc cga ttg ca 20bp 
86bp 
for ctt ctg cga ttt cgg ctc c 19p 
Ctgf NM010217 
rev tgc ttt gga agg act cac cg 20bp 
115bp 
for tgg ctg tca aga tga tag aag tac tga 27bp 
Cyclin G1 NM009831 
rev tgg ctg aca tct aga ctc ctg ttc 24bp 
94bp 
for gtc aac aag cag ccg aaa cc 20bp 
Cyclin B2 NM007630 
rev gag gac gat cct tgg gag cta 2qbp 
75bp 
for cca ccg ctc tga aag gga t 19bp 
Cyr61 NM010516 
rev ccc cgt ttt ggt aga ttc tgg 21bp 
80bp 
for tat gaa cag atg ggc ctc ctg 21bp 
Fizz1 NM020509 
rev tcc act ctg gat ctc cca aga 21bp 
90bp 
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for gtg tag cac aac ttc caa tta cga a 25bp 
Fn NM010233 
rev gga att tcc gcc tcg agt ct 20bp 
90bp 
for agg agc tac tga cca ggg agc t 22bp 
Fsp1 NM011311 
rev tca ttg tcc ctg ttg ctg tcc 21bp 
102bp 
for aaa cag cac agg ttc tgc aaa a 22bp 
Fzd1 NM021457 
rev tgg gcc ctc tcg ttc ctt 18bp 
58bp 
for tcc atc tgg tgg gtg att ctg 21bp 
Fzd2 NM020510 
rev ctc gtg gcc cca ctt cat t 19bp 
66bp 
for gcc tat agc gag tgt tca aaa ctc a 25bp 
Fzd3 NM021458 
rev tgg aaa cct act gca ctc cat atc t 25bp 
78bp 
for gcc cca gaa cga cca caa 18bp 
Fzd4 NM008055 
rev ggg caa ggg aac ctc ttc at 20bp 
64bp 
for ttt gag ctg gta ccc tag gat ga 23bp 
Gsk3β NM_019827 
rev ttc ttc gct ttc cga tgc a 19bp 
75bp 
for atg tcc ggt aac ggc ggc  22bp 
Hmbs NM013551 
rev ggt aca agg ctt tca gca tcg c 18bp 
135bp 
for gga ggg ccg aaa tga atg a 19bp 
Inha NM008380 
rev tgc agt gtc ttc ctg gct gt 20bp 
84bp 
for ggt ctc ctg cat tgc tca cat 21bp 
Kcne2 NM134110 
rev cat cct cca gtg tct ggg tca 21bp 
82bp 
for ttg acc gct cct tta ggt atg aa 23bp 
Ki67 NM001081 117 
rev ggt atc ttg acc ttc ccc atc a 22bp 
138bp 
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for ggc ggc gtt gga cag at 17bp 
Lef1 NM010703 
rev cac ccg tga tgg gat aaa cag 21bp 
67bp 
for caa cgt gga cgt gtt tta ttc ttc 24bp 
Lrp5 NM008513 
rev cag cga ctg gtg ctg tag tca 21bp 
138bp 
for cca ttc ctc tca ctg gtg tca a 22bp 
Lrp6 NM008514 
rev gcc aaa ctc tac cac atg ttc ca 23bp 
146bp 
for atc gag acc atg cgg aag c 19bp 
Mmp2 NM008610 
rev atc cac ggt ttc agg gtc c 19bp 
123bp 
for cct agg cgg aga tgc tca ct 20bp 
Mmp7 NM010810 
rev gct gcc acc cat gaa ttt g 19bp 
96bp 
for cgc ctt ggt gta gca caa ca 20bp 
Mmp9 NM01399 
rev aca ggg ttt gcc ttc tcc gtt 21bp 
106bp 
for aac aac cag act ggc att tgc 21bp 
Nov NM010930 
rev cag cca atc tgc cca tct ct 20bp 
133bp 
for gtc ttt ccg acc aag agc ag 20bp 
Pai1 NM008871 
rev gac aaa ggc tgt gga gga ag 20bp 
104bp 
for gta caa ccg tgt gtc ctc cat 21bp 
Sfrp1 NM013834 
rev cat cct cag tgc aaa ctc gct 21bp 
89bp 
for gct ggt gat gat gct ccc a 19bp 
αSMA NM007392 
rev gcc cat tcc aac cat tac tcc 21bp 
80bp 
for gtt tgg cat tgc ctc ctc c 19bp 
Spp1 NM009263 
rev gga tct ggg tgc agg ctg ta 20bp 
83bp 
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for tcc agc aca ctt gtc caa caa 21bp 
Tcf3 NM009332 
rev cag cgg gtg cat gtg atg 18bp 
61bp 
for gtg gga act gcc ccg ttt 18bp 
Tcf4 NM009333 
rev gtt cta aga gca cag ggc agt tg 23bp 
59bp 
for gtc ctg agg gtg ggc aac at 20bp 
Wisp1 NM018865 
rev ggg cgt gta gtc gtt tcc tct 21bp 
97bp 
for tac agg tgc cag gaa ggt gc 20bp 
Wisp2 NM016873 
rev cag atg cag gag tga caa ggg 21bp 
119bp 
for ggc gtg tgc gca tat ctt g 19bp 
Wisp3 XM282903 
rev agg cag ctg aac agt ggg tg 20bp 
98bp 
for caa atg gca att ccg aaa cc 20bp 
Wnt1 NM021279 
rev gat tgc gaa gat gaa cgc tg 20bp 
112bp 
for agc cct gat gaa cct tca caa c 22bp 
Wnt2 NM023653 
rev tga cac ttg cat tct tgt ttc aag 24bp 
78bp 
for gca cca ccg tca gca aca 18bp 
Wnt3a NM009522 
rev ggg tgg ctt tgt cca gaa ca 20bp 
57bp 
for tcg aaa gtg gat ctt tta cgt gtt t 25bp 
Wnt7b NM009528 
rev tga caa tgc tcc gag ctt ca 20bp 
67bp 
for tgg gac gcc agg tgg taa 18bp 
Wnt10b NM011718 
rev ctg acg ttc cat ggc att tg 20bp 
60bp 
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Figure S1. Control negative immunostaining for the antibodies used in the study. Cells were 
prepared as described, irrelevant IgG used in replacement of a specific primary antibody, and 
secondary antibodies used as indicated (magnification 10×). 
 
 
Figure S2. Control immunohistochemical staining of sections from control (transplant donor) or 
IPF lung tissue specimen for the WISP1 antibody used in Figure 6D and 6E. The antibody was 
preincubated with recombinant human WISP1 protein before processing. 
rabbit alexa 488 FITC rat alexa 555 
FITC+ rabbit alexa 555 FITC+ rat alexa 555 rabbit alexa 555 
αWISP1 after preincubation with rhWISP1 
Donor 
IPF 
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